SHANGHAI – Pick an issue or an industry, China’s complex problems can seem intractable with much-touted reforms dismally ineffectual. But with the power of China’s top-down decision-making, there are times when the government sets a new course and far-reaching change follows swiftly if not necessarily smoothly.

SHANGHAI – Clinical-stage immuno-oncology company, Beigene Co. Ltd., of Beijing, has announced its intention to raise $100 million on Nasdaq. A member of the small but growing group of rising biotech stars in China, Beigene filed IPO intentions to sell American depository shares with the SEC as an emerging growth company with reduced filing requirements. Pricing terms were undisclosed.

SHANGHAI – Hutchison Medipharma Ltd., a Shanghai-based drug R&D subsidiary of Hutchison China Meditech, with its partner Astrazeneca plc, enrolled 90 patients at 22 sites in a global phase II trial for savolitinib (AZD6094) in papillary renal cell carcinoma (PRCC), a type of cancer that afflicts 48,000 people annually, or about 14 percent of new cases of kidney cancer in the world.

SHANGHAI – Clinical-stage immuno-oncology company, Beigene Co. Ltd., of Beijing, has announced its intention to raise $100 million on Nasdaq.

SHANGHAI – Hutchison Medipharma Ltd., a Shanghai-based drug R&D subsidiary of Hutchison China Meditech, with its partner Astrazeneca plc, enrolled 90 patients at 22 sites in a global phase II trial for savolitinib (AZD6094) in papillary renal cell carcinoma (PRCC), a type of cancer that afflicts 48,000 people annually, or about 14 percent of new cases of kidney cancer in the world.

SHANGHAI – Since July, innovation has been on a remarkable roll in the world of new drug discovery and development in China.

SHANGHAI – Eli Lilly and Co. has deepened its relationship with Chinese biotech, Innovent Biologics Inc. in an immuno-oncology deal worth potentially $1 billion in milestone and royalty payments if all goes according to plan over the next decade.

SHANGHAI – Since July, innovation has been on a remarkable roll in the world of new drug discovery and development in China.

SHANGHAI – Eli Lilly and Co. has deepened its relationship with Chinese biotech, Innovent Biologics Inc. in an immuno-oncology deal worth potentially $1 billion in milestone and royalty payments if all goes according to plan over the next decade.

SHANGHAI – Wechat, China's version of Twitter, broke out in excitement and some surprise when the Nobel prize went public this week. It took a modest researcher with no PhD in her eighth decade to land China's first Nobel Prize for Medicine or Physiology.